Cerebrovascular diseases are currently among the three primary causes of death worldwide and are the irst cause of disability in adults. Nevertheless, there are no neuroprotective or neurorestorative therapies that have shown considerable beneicial efects, except for the FD"-approved recombinant tissue plasminogen activator rtP" , which has been used for decades for the treatment of stroke and its efectiveness is still controversial. This is why it is very important to develop efective therapeutic options. In order to achieve this objective, it is essential to recognize the secondary mechanisms involved in the pathological development. The immunological system is one of these mechanisms that participate during the acute and chronic phases of disease, both in deleterious and beneicial manners. It is known that the immune system's duality contributes to the ischemic injury through proinlammatory cytokine tumor necrosis factor-TNF-, interleukin-1 IL-1 , interleukin-6 IL-6 , and oxygen reactive species production, etc. Nevertheless, it also provides protection and even restoration through anti-inlammatory cytokine interleukin-4 IL-4 , interleukin-10 IL-10 , transforming growth factor-TGF-, and growth factor brain-derived neurotrophic factor "DNF , insulin-like growth factor-1 IGF-1 , neurotrophin-3 NT-3 , neurotrophin-4 NT-4 production. This states that innovative therapeutic options must be proposed with the goal of protecting and restoring the tissue after the ischemic event. Such therapies are exposed in the present chapter.